[{"address1": "117, Avenue de Luminy", "address2": "BP 30191", "city": "Marseille", "zip": "13009", "country": "France", "phone": "33 4 30 30 30 30", "fax": "33 4 30 30 30 00", "website": "https://www.innate-pharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory s\u00e9zary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.", "fullTimeEmployees": 174, "companyOfficers": [{"maxAge": 1, "name": "Mr. Jonathan E. Dickinson B.Sc., M.B.A.", "age": 56, "title": "CEO & Director", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 130439, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yannis  Morel Ph.D.", "age": 51, "title": "Executive VP & COO", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 503345, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sonia  Quaratino M.D., Ph.D.", "age": 62, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 574525, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Fran\u00e7ois  Romagn\u00e9 Ph.D.", "age": 60, "title": "Founder", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric  Vivier D.V.M., M.B.A., Ph.D.", "age": 60, "title": "Founder, Senior VP & Chief Scientific Officer", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Bonneville Ph.D.", "age": 64, "title": "Founder", "yearBorn": 1960, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jean Jacques Fourni\u00e9 Ph.D.", "title": "Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alessandro  Moretta M.D., Ph.D.", "title": "Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frederic  Lombard M.B.A.", "age": 49, "title": "Senior VP & CFO", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Henry  Wheeler M.Sc.", "age": 40, "title": "Vice President of Investor Relations & Communication", "yearBorn": 1984, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.0099, "open": 2.05, "dayLow": 2.0442, "dayHigh": 2.0953, "regularMarketPreviousClose": 2.0099, "regularMarketOpen": 2.05, "regularMarketDayLow": 2.0442, "regularMarketDayHigh": 2.0953, "payoutRatio": 0.0, "beta": 0.8, "forwardPE": 4.566667, "volume": 13749, "regularMarketVolume": 13749, "averageVolume": 13750, "averageVolume10days": 21490, "averageDailyVolume10Day": 21490, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 192415680, "fiftyTwoWeekLow": 1.29, "fiftyTwoWeekHigh": 3.511, "allTimeHigh": 11.95, "allTimeLow": 1.29, "priceToSalesTrailing12Months": 15.227578, "fiftyDayAverage": 2.06872, "twoHundredDayAverage": 2.00255, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 156386272, "profitMargins": 0.0, "floatShares": 59218758, "sharesOutstanding": 92166898, "sharesShort": 46368, "sharesShortPriorMonth": 52047, "sharesShortPreviousMonthDate": 1755216000, "dateShortInterest": 1757894400, "sharesPercentSharesOut": 0.0005, "heldPercentInsiders": 0.0, "heldPercentInstitutions": 0.0017299999, "shortRatio": 4.59, "shortPercentOfFloat": 0.00059999997, "impliedSharesOutstanding": 93632932, "bookValue": 0.056, "priceToBook": 36.69643, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -46051000, "trailingEps": -0.65, "forwardEps": 0.45, "enterpriseToRevenue": 12.376, "enterpriseToEbitda": -3.142, "52WeekChange": -0.0024271607, "SandP52WeekChange": 0.17904854, "quoteType": "EQUITY", "currentPrice": 2.055, "targetHighPrice": 8.0, "targetLowPrice": 2.0, "targetMeanPrice": 4.19667, "targetMedianPrice": 2.59, "recommendationKey": "none", "numberOfAnalystOpinions": 3, "totalCash": 60027000, "totalCashPerShare": 0.651, "ebitda": -49771000, "totalDebt": 27029000, "quickRatio": 2.081, "currentRatio": 2.208, "totalRevenue": 12636000, "debtToEquity": 525.447, "revenuePerShare": 0.15, "returnOnAssets": -0.25922, "returnOnEquity": -2.71367, "grossProfits": -30788000, "freeCashflow": -20764000, "operatingCashflow": -41096000, "revenueGrowth": -0.606, "grossMargins": -2.43653, "ebitdaMargins": 0.0, "operatingMargins": -5.23189, "financialCurrency": "EUR", "symbol": "IPHA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketPrice": 2.055, "regularMarketChangePercent": 2.2438912, "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "esgPopulated": false, "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 13750, "fiftyTwoWeekLowChange": 0.7650001, "fiftyTwoWeekLowChangePercent": 0.59302336, "fiftyTwoWeekRange": "1.29 - 3.511", "fiftyTwoWeekHighChange": -1.4559999, "fiftyTwoWeekHighChangePercent": -0.41469663, "fiftyTwoWeekChangePercent": -0.24271607, "earningsTimestamp": 1763037000, "earningsTimestampStart": 1763037000, "earningsTimestampEnd": 1763037000, "earningsCallTimestampStart": 1758110400, "earningsCallTimestampEnd": 1758110400, "isEarningsDateEstimate": false, "corporateActions": [], "regularMarketTime": 1759521600, "exchange": "NMS", "messageBoardId": "finmb_426137", "market": "us_market", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1571319000000, "regularMarketChange": 0.045099974, "regularMarketDayRange": "2.0442 - 2.0953", "epsTrailingTwelveMonths": -0.65, "epsForward": 0.45, "epsCurrentYear": -0.658, "priceEpsCurrentYear": -3.1231005, "fiftyDayAverageChange": -0.013720036, "fiftyDayAverageChangePercent": -0.006632137, "twoHundredDayAverageChange": 0.05245018, "twoHundredDayAverageChangePercent": 0.026191697, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "shortName": "Innate Pharma S.A.", "longName": "Innate Pharma S.A.", "marketState": "CLOSED", "displayName": "Innate Pharma", "trailingPegRatio": null, "__fetch_time": "2025-10-04"}]